Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

A molecular computational model improves the preoperative diagnosis of thyroid nodules

Authors: Sara Tomei, Ivo Marchetti, Katia Zavaglia, Francesca Lessi, Alessandro Apollo, Paolo Aretini, Giancarlo Di Coscio, Generoso Bevilacqua, Chiara Mazzanti

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Thyroid nodules with indeterminate cytological features on fine needle aspiration (FNA) cytology have a 20% risk of thyroid cancer. The aim of the current study was to determine the diagnostic utility of an 8-gene assay to distinguish benign from malignant thyroid neoplasm.

Methods

The mRNA expression level of 9 genes (KIT, SYNGR2, C21orf4, Hs.296031, DDI2, CDH1, LSM7, TC1, NATH) was analysed by quantitative PCR (q-PCR) in 93 FNA cytological samples. To evaluate the diagnostic utility of all the genes analysed, we assessed the area under the curve (AUC) for each gene individually and in combination. BRAF exon 15 status was determined by pyrosequencing. An 8-gene computational model (Neural Network Bayesian Classifier) was built and a multiple-variable analysis was then performed to assess the correlation between the markers.

Results

The AUC for each significant marker ranged between 0.625 and 0.900, thus all the significant markers, alone and in combination, can be used to distinguish between malignant and benign FNA samples. The classifier made up of KIT, CDH1, LSM7, C21orf4, DDI2, TC1, Hs.296031 and BRAF had a predictive power of 88.8%. It proved to be useful for risk stratification of the most critical cytological group of the indeterminate lesions for which there is the greatest need of accurate diagnostic markers.

Conclusion

The genetic classification obtained with this model is highly accurate at differentiating malignant from benign thyroid lesions and might be a useful adjunct in the preoperative management of patients with thyroid nodules.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mazzaferri EL: Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med. 1992, 93 (4): 359-362. 10.1016/0002-9343(92)90163-6.CrossRefPubMed Mazzaferri EL: Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med. 1992, 93 (4): 359-362. 10.1016/0002-9343(92)90163-6.CrossRefPubMed
2.
go back to reference Ross DS: Nonpalpable thyroid nodules–managing an epidemic. J Clin Endocrinol Metab. 2002, 87 (5): 1938-1940. 10.1210/jc.87.5.1938.PubMed Ross DS: Nonpalpable thyroid nodules–managing an epidemic. J Clin Endocrinol Metab. 2002, 87 (5): 1938-1940. 10.1210/jc.87.5.1938.PubMed
3.
go back to reference Segev DL, Clark DP, Zeiger MA, Umbricht C: Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol. 2003, 47 (5): 709-722. 10.1159/000326594.CrossRefPubMed Segev DL, Clark DP, Zeiger MA, Umbricht C: Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol. 2003, 47 (5): 709-722. 10.1159/000326594.CrossRefPubMed
4.
go back to reference Baloch ZW, LiVolsi VA: The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. Am J Clin Pathol. 2002, 118 (2): 165-166. 10.1309/CEAQ-VRFW-FJBQ-AM5M.CrossRefPubMed Baloch ZW, LiVolsi VA: The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. Am J Clin Pathol. 2002, 118 (2): 165-166. 10.1309/CEAQ-VRFW-FJBQ-AM5M.CrossRefPubMed
5.
go back to reference Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E: Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?. Cancer. 2008, 113 (5): 930-935. 10.1002/cncr.23703.CrossRefPubMed Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E: Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?. Cancer. 2008, 113 (5): 930-935. 10.1002/cncr.23703.CrossRefPubMed
6.
go back to reference Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004, 64 (8): 2898-2903. 10.1158/0008-5472.CAN-03-3811.CrossRefPubMed Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004, 64 (8): 2898-2903. 10.1158/0008-5472.CAN-03-3811.CrossRefPubMed
7.
go back to reference Tomei S, Mazzanti C, Marchetti I, Rossi L, Zavaglia K, Lessi F, Apollo A, Aretini P, Di Coscio G, Bevilacqua G: c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med. 2012, 10 (1): 7-10.1186/1479-5876-10-7.CrossRefPubMedPubMedCentral Tomei S, Mazzanti C, Marchetti I, Rossi L, Zavaglia K, Lessi F, Apollo A, Aretini P, Di Coscio G, Bevilacqua G: c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med. 2012, 10 (1): 7-10.1186/1479-5876-10-7.CrossRefPubMedPubMedCentral
8.
go back to reference Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J, Kong X, Varhaug JE, Lillehaug JR: Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem. 2006, 7: 13-10.1186/1471-2091-7-13.CrossRefPubMedPubMedCentral Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J, Kong X, Varhaug JE, Lillehaug JR: Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem. 2006, 7: 13-10.1186/1471-2091-7-13.CrossRefPubMedPubMedCentral
9.
go back to reference Chua EL, Young L, Wu WM, Turtle JR, Dong Q: Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics. 2000, 69 (3): 342-347. 10.1006/geno.2000.6348.CrossRefPubMed Chua EL, Young L, Wu WM, Turtle JR, Dong Q: Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics. 2000, 69 (3): 342-347. 10.1006/geno.2000.6348.CrossRefPubMed
10.
go back to reference Fluge O, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR: NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene. 2002, 21 (33): 5056-5068. 10.1038/sj.onc.1205687.CrossRefPubMed Fluge O, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR: NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene. 2002, 21 (33): 5056-5068. 10.1038/sj.onc.1205687.CrossRefPubMed
11.
go back to reference Sargent DJ: Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer. 2001, 91 (8 Suppl): 1636-1642.CrossRefPubMed Sargent DJ: Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer. 2001, 91 (8 Suppl): 1636-1642.CrossRefPubMed
12.
go back to reference Kedra D, Pan HQ, Seroussi E, Fransson I, Guilbaud C, Collins JE, Dunham I, Blennow E, Roe BA, Piehl F, et al: Characterization of the human synaptogyrin gene family. Hum Genet. 1998, 103 (2): 131-141. 10.1007/s004390050795.CrossRefPubMed Kedra D, Pan HQ, Seroussi E, Fransson I, Guilbaud C, Collins JE, Dunham I, Blennow E, Roe BA, Piehl F, et al: Characterization of the human synaptogyrin gene family. Hum Genet. 1998, 103 (2): 131-141. 10.1007/s004390050795.CrossRefPubMed
13.
go back to reference Olesen C, Nyeng P, Kalisz M, Jensen TH, Moller M, Tommerup N, Byskov AG: Global gene expression analysis in fetal mouse ovaries with and without meiosis and comparison of selected genes with meiosis in the testis. Cell Tissue Res. 2007, 328 (1): 207-221. 10.1007/s00441-006-0205-5.CrossRefPubMed Olesen C, Nyeng P, Kalisz M, Jensen TH, Moller M, Tommerup N, Byskov AG: Global gene expression analysis in fetal mouse ovaries with and without meiosis and comparison of selected genes with meiosis in the testis. Cell Tissue Res. 2007, 328 (1): 207-221. 10.1007/s00441-006-0205-5.CrossRefPubMed
14.
go back to reference Tharun S, He W, Mayes AE, Lennertz P, Beggs JD, Parker R: Yeast Sm-like proteins function in mRNA decapping and decay. Nature. 2000, 404 (6777): 515-518. 10.1038/35006676.CrossRefPubMed Tharun S, He W, Mayes AE, Lennertz P, Beggs JD, Parker R: Yeast Sm-like proteins function in mRNA decapping and decay. Nature. 2000, 404 (6777): 515-518. 10.1038/35006676.CrossRefPubMed
15.
go back to reference Conte N, Charafe-Jauffret E, Delaval B, Adelaide J, Ginestier C, Geneix J, Isnardon D, Jacquemier J, Birnbaum D: Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene. 2002, 21 (36): 5619-5630. 10.1038/sj.onc.1205658.CrossRefPubMed Conte N, Charafe-Jauffret E, Delaval B, Adelaide J, Ginestier C, Geneix J, Isnardon D, Jacquemier J, Birnbaum D: Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene. 2002, 21 (36): 5619-5630. 10.1038/sj.onc.1205658.CrossRefPubMed
16.
go back to reference Moldrich RX, Laine J, Visel A, Beart PM, Laffaire J, Rossier J, Potier MC: Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain. Neuroscience. 2008, 154 (4): 1255-1266. 10.1016/j.neuroscience.2008.01.089.CrossRefPubMed Moldrich RX, Laine J, Visel A, Beart PM, Laffaire J, Rossier J, Potier MC: Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain. Neuroscience. 2008, 154 (4): 1255-1266. 10.1016/j.neuroscience.2008.01.089.CrossRefPubMed
17.
go back to reference Hardy RG, Vicente-Duenas C, Gonzalez-Herrero I, Anderson C, Flores T, Hughes S, Tselepis C, Ross JA, Sanchez-Garcia I: Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol. 2007, 171 (3): 1037-1046. 10.2353/ajpath.2007.061211.CrossRefPubMedPubMedCentral Hardy RG, Vicente-Duenas C, Gonzalez-Herrero I, Anderson C, Flores T, Hughes S, Tselepis C, Ross JA, Sanchez-Garcia I: Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol. 2007, 171 (3): 1037-1046. 10.2353/ajpath.2007.061211.CrossRefPubMedPubMedCentral
18.
go back to reference Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005, 90 (7): 4011-4018. 10.1210/jc.2005-0313.CrossRefPubMed Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005, 90 (7): 4011-4018. 10.1210/jc.2005-0313.CrossRefPubMed
19.
go back to reference Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP, Death AK: TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res. 2004, 64 (8): 2766-2773. 10.1158/0008-5472.CAN-03-2093.CrossRefPubMed Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP, Death AK: TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res. 2004, 64 (8): 2766-2773. 10.1158/0008-5472.CAN-03-2093.CrossRefPubMed
20.
go back to reference Ginzinger DG: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002, 30 (6): 503-512. 10.1016/S0301-472X(02)00806-8.CrossRefPubMed Ginzinger DG: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002, 30 (6): 503-512. 10.1016/S0301-472X(02)00806-8.CrossRefPubMed
21.
go back to reference Ohlsson L, Hammarstrom ML, Israelsson A, Naslund L, Oberg A, Lindmark G, Hammarstrom S: Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer. 2006, 95 (2): 218-225. 10.1038/sj.bjc.6603206.CrossRefPubMedPubMedCentral Ohlsson L, Hammarstrom ML, Israelsson A, Naslund L, Oberg A, Lindmark G, Hammarstrom S: Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer. 2006, 95 (2): 218-225. 10.1038/sj.bjc.6603206.CrossRefPubMedPubMedCentral
22.
go back to reference Schroder CP, Ruiters MH, de Jong S, Tiebosch AT, Wesseling J, Veenstra R, de Vries J, Hoekstra HJ, de Leij LF, de Vries EG: Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer. 2003, 106 (4): 611-618. 10.1002/ijc.11295.CrossRefPubMed Schroder CP, Ruiters MH, de Jong S, Tiebosch AT, Wesseling J, Veenstra R, de Vries J, Hoekstra HJ, de Leij LF, de Vries EG: Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer. 2003, 106 (4): 611-618. 10.1002/ijc.11295.CrossRefPubMed
23.
go back to reference Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK: A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005, 138 (6): 1050-1056. 10.1016/j.surg.2005.09.010. discussion 1056–1057CrossRefPubMed Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK: A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005, 138 (6): 1050-1056. 10.1016/j.surg.2005.09.010. discussion 1056–1057CrossRefPubMed
24.
go back to reference Baranwal S, Alahari SK: Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009, 384 (1): 6-11. 10.1016/j.bbrc.2009.04.051.CrossRefPubMedPubMedCentral Baranwal S, Alahari SK: Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun. 2009, 384 (1): 6-11. 10.1016/j.bbrc.2009.04.051.CrossRefPubMedPubMedCentral
25.
go back to reference Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004, 4 (2): 118-132. 10.1038/nrc1276.CrossRefPubMed Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004, 4 (2): 118-132. 10.1038/nrc1276.CrossRefPubMed
26.
go back to reference Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28 (1–2): 151-166.CrossRefPubMed Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28 (1–2): 151-166.CrossRefPubMed
27.
go back to reference Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, Park J, Koo H, Moon RT, Song K, et al: TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. Cancer Res. 2006, 66 (2): 723-728. 10.1158/0008-5472.CAN-05-3124.CrossRefPubMed Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, Park J, Koo H, Moon RT, Song K, et al: TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. Cancer Res. 2006, 66 (2): 723-728. 10.1158/0008-5472.CAN-05-3124.CrossRefPubMed
28.
go back to reference Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P: Bayesian forecasting of serum gentamicin concentrations in intensive care patients. Clin Pharmacokinet. 1990, 18 (5): 409-418. 10.2165/00003088-199018050-00005.CrossRefPubMed Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P: Bayesian forecasting of serum gentamicin concentrations in intensive care patients. Clin Pharmacokinet. 1990, 18 (5): 409-418. 10.2165/00003088-199018050-00005.CrossRefPubMed
29.
go back to reference Wakefield J, Racine-Poon A: An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Stat Med. 1995, 14 (9–10): 971-986.CrossRefPubMed Wakefield J, Racine-Poon A: An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Stat Med. 1995, 14 (9–10): 971-986.CrossRefPubMed
30.
go back to reference Burnside ES, Rubin DL, Fine JP, Shachter RD, Sisney GA, Leung WK: Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: initial experience. Radiology. 2006, 240 (3): 666-673. 10.1148/radiol.2403051096.CrossRefPubMed Burnside ES, Rubin DL, Fine JP, Shachter RD, Sisney GA, Leung WK: Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: initial experience. Radiology. 2006, 240 (3): 666-673. 10.1148/radiol.2403051096.CrossRefPubMed
31.
go back to reference Christiansen CL, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, Fletcher SW: Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 2000, 92 (20): 1657-1666. 10.1093/jnci/92.20.1657.CrossRefPubMed Christiansen CL, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, Fletcher SW: Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 2000, 92 (20): 1657-1666. 10.1093/jnci/92.20.1657.CrossRefPubMed
32.
go back to reference Edwards FH, Schaefer PS, Cohen AJ, Bellamy RF, Thompson L, Graeber GM, Barry MJ: Use of artificial intelligence for the preoperative diagnosis of pulmonary lesions. Ann Thorac Surg. 1989, 48 (4): 556-559. 10.1016/S0003-4975(10)66862-2.CrossRefPubMed Edwards FH, Schaefer PS, Cohen AJ, Bellamy RF, Thompson L, Graeber GM, Barry MJ: Use of artificial intelligence for the preoperative diagnosis of pulmonary lesions. Ann Thorac Surg. 1989, 48 (4): 556-559. 10.1016/S0003-4975(10)66862-2.CrossRefPubMed
33.
go back to reference Burd RS, Ouyang M, Madigan D: Bayesian logistic injury severity score: a method for predicting mortality using international classification of disease-9 codes. Acad Emerg Med. 2008, 15 (5): 466-475. 10.1111/j.1553-2712.2008.00105.x.CrossRefPubMed Burd RS, Ouyang M, Madigan D: Bayesian logistic injury severity score: a method for predicting mortality using international classification of disease-9 codes. Acad Emerg Med. 2008, 15 (5): 466-475. 10.1111/j.1553-2712.2008.00105.x.CrossRefPubMed
34.
go back to reference Fazio VW, Tekkis PP, Remzi F, Lavery IC: Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum. 2004, 47 (12): 2015-2024. 10.1007/s10350-004-0704-y.CrossRefPubMed Fazio VW, Tekkis PP, Remzi F, Lavery IC: Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum. 2004, 47 (12): 2015-2024. 10.1007/s10350-004-0704-y.CrossRefPubMed
35.
go back to reference Biagioli B, Scolletta S, Cevenini G, Barbini E, Giomarelli P, Barbini P: A multivariate Bayesian model for assessing morbidity after coronary artery surgery. Crit Care. 2006, 10 (3): R94-10.1186/cc4951.CrossRefPubMedPubMedCentral Biagioli B, Scolletta S, Cevenini G, Barbini E, Giomarelli P, Barbini P: A multivariate Bayesian model for assessing morbidity after coronary artery surgery. Crit Care. 2006, 10 (3): R94-10.1186/cc4951.CrossRefPubMedPubMedCentral
36.
go back to reference Edwards FH, Peterson RF, Bridges C, Ceithaml EL: 1988: use of a Bayesian statistical model for risk assessment in coronary artery surgery. Updated in 1995. Ann Thorac Surg. 1995, 59 (6): 1611-1612. 10.1016/0003-4975(95)00189-R.CrossRefPubMed Edwards FH, Peterson RF, Bridges C, Ceithaml EL: 1988: use of a Bayesian statistical model for risk assessment in coronary artery surgery. Updated in 1995. Ann Thorac Surg. 1995, 59 (6): 1611-1612. 10.1016/0003-4975(95)00189-R.CrossRefPubMed
37.
go back to reference Hoot N, Aronsky D: Using Bayesian networks to predict survival of liver transplant patients. AMIA Annu Symp Proc. 2005, 2005: 345-349.PubMedCentral Hoot N, Aronsky D: Using Bayesian networks to predict survival of liver transplant patients. AMIA Annu Symp Proc. 2005, 2005: 345-349.PubMedCentral
38.
go back to reference Lenihan CR, O'Kelly P, Mohan P, Little D, Walshe JJ, Kieran NE, Conlon PJ: MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Ren Fail. 2008, 30 (4): 345-352. 10.1080/08860220801947686.CrossRefPubMed Lenihan CR, O'Kelly P, Mohan P, Little D, Walshe JJ, Kieran NE, Conlon PJ: MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Ren Fail. 2008, 30 (4): 345-352. 10.1080/08860220801947686.CrossRefPubMed
Metadata
Title
A molecular computational model improves the preoperative diagnosis of thyroid nodules
Authors
Sara Tomei
Ivo Marchetti
Katia Zavaglia
Francesca Lessi
Alessandro Apollo
Paolo Aretini
Giancarlo Di Coscio
Generoso Bevilacqua
Chiara Mazzanti
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-396

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine